Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 May 1;90(2):194-201.
doi: 10.1093/cvr/cvr071.

Glucose metabolism and cardiac hypertrophy

Affiliations
Review

Glucose metabolism and cardiac hypertrophy

Stephen C Kolwicz Jr et al. Cardiovasc Res. .

Abstract

The most notable change in the metabolic profile of hypertrophied hearts is an increased reliance on glucose with an overall reduced oxidative metabolism, i.e. a reappearance of the foetal metabolic pattern. In animal models, this change is attributed to the down-regulation of the transcriptional cascades promoting gene expression for fatty acid oxidation and mitochondrial oxidative phosphorylation in adult hearts. Impaired myocardial energetics in cardiac hypertrophy also triggers AMP-activated protein kinase (AMPK), leading to increased glucose uptake and glycolysis. Aside from increased reliance on glucose as an energy source, changes in other glucose metabolism pathways, e.g. the pentose phosphate pathway, the glucosamine biosynthesis pathway, and anaplerosis, are also noted in the hypertrophied hearts. Studies using transgenic mouse models and pharmacological compounds to mimic or counter the switch of substrate preference in cardiac hypertrophy have demonstrated that increased glucose metabolism in adult heart is not harmful and can be beneficial when it provides sufficient fuel for oxidative metabolism. However, improvement in the oxidative capacity and efficiency rather than the selection of the substrate is likely the ultimate goal for metabolic therapies.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Glucose metabolism pathways. 6-PG, 6-phosphogluconate; 6-PGL, 6-phosphoglucono-δ-lactone; AR, aldose reductase; F-6-P, fructose-6-phosphate; F-1,6,-BP, fructose-1,6-bisphosphate; G-6-P, glucose-6-phosphate; GFAT, glutamine fructose-6-phosphate amidotransferase; G6PD: glucose-6-phosphate dehydrogenase; NAD+, nicotinamide adenine dinucleotide; NADH, reduced nicotinamide adenine dinucleotide; NADP+, nicotinamide adenine dinucleotide phosphate; NADPH, reduced nicotinamide adenine dinucleotide phosphate; R-5-P, ribose-5-phosphate; SDH, sorbitol dehydrogenase; UDPGlcNAc, uridine diphosphate-N-acetylglucosamine; X-5-P, xylose-5-phosphate.
Figure 2
Figure 2
Altered glucose metabolism in cardiac hypertrophy. Key changes in the metabolic pathway have been colour coded. Green: increased; Red: decreased; Blue: no change; Black: unknown. F-6-P, fructose-6-phosphate; G-6-P, glucose-6-phosphate; G6PD, glucose-6-phosphate dehydrogenase; GFAT, glutamine fructose-6-phosphate amidotransferase; GLUT, glucose transporter; LDH, lactate dehydrogenase; ME, malic enzyme; NADH, reduced nicotinamide adenine dinucleotide; OMC, oxoglutarate-malate carrier; TCA, tricarboxylic acid.

References

    1. Kresge N, Simoni RD, Hill RL. Otto Fritz Meyerhof and the elucidation of the glycolytic pathway. J Biol Chem. 2005;280:e3. - PubMed
    1. Kornberg H. Krebs and his trinity of cycles. Nat Rev Mol Cell Biol. 2000;1:225–228. - PubMed
    1. Mitchell P. Coupling of phosphorylation to electron and hydrogen transfer by a chemi-osmotic type of mechanism. Nature. 1961;191:144–148. - PubMed
    1. Hasin Y, Barry WH. Myocardial metabolic inhibition and membrane potential, contraction, and potassium uptake. Am J Physiol. 1984;247:H322–H329. - PubMed
    1. Nakamura K, Kusuoka H, Ambrosio G, Becker LC. Glycolysis is necessary to preserve myocardial Ca2+ homeostasis during beta-adrenergic stimulation. Am J Physiol. 1993;264:H670–H678. - PubMed

Publication types